Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to a deferred bonus plan.
- Share Price: 1,358.50 pence per Ordinary Share and $44.13 per ADS.
- Transaction Type: Re-investment of dividends paid to shareholders on January 3, 2013.
Material Changes
The filing reports increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for specific executives. These changes result from the re-investment of dividends and do not represent material changes to the company's overall financial position or operations.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- Executive Participation: Multiple senior executives, including Sir Andrew Witty, participated in the 2009 Deferred Annual Bonus Plan.
- Transaction Volume: Acquisitions ranged from 66 ADSs (Mr. W C Louv) to 1,494 Ordinary Shares (Sir Andrew Witty) per element (personal and matching).
- Valuation Basis: All transactions were executed at a price of 1,358.50 pence per Ordinary Share.
- Regulatory Compliance: The notification was made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).